Wout A P Breeman
Overview
Explore the profile of Wout A P Breeman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Capello A, Krenning E, Bernard B, Breeman W, van Hagen M, de Jong M
J Nucl Med
. 2004 Oct;
45(10):1716-20.
PMID: 15471839
Unlabelled: Receptor-targeted scintigraphy and radionuclide therapy with radiolabeled somatostatin analogs are successfully applied for somatostatin receptor-positive tumors. The synergistic effects of an apoptosis-inducing factor, for example, the Arg-Gly-Asp (RGD) motif,...
12.
Capello A, Krenning E, Breeman W, Bernard B, Konijnenberg M, de Jong M
Cancer Biother Radiopharm
. 2003 Nov;
18(5):761-8.
PMID: 14629824
Somatostatin analogs promising for peptide receptor scintigraphy (PRS) and peptide receptor radionuclide therapy (PRRT) are D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr(ol) (Tyr 3-octreotide) and D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr (tyr3-octreotate). For radiotherapeutic applications these peptides are being labeled with...
13.
Hofland L, Lamberts S, van Hagen P, Reubi J, Schaeffer J, Waaijers M, et al.
J Nucl Med
. 2003 Aug;
44(8):1315-21.
PMID: 12902423
Unlabelled: Human somatostatin (SS) receptor (sst)-positive tumors can be visualized by gamma camera scintigraphy after the injection of [(111)In-diethylenetriaminepentaacetic acid (DTPA)-D-Phe(1)] octreotide. Uptake of [(111)In-DTPA-D-Phe(1)]octreotide is dependent on sst-mediated internalization...
14.
Capello A, Krenning E, Breeman W, Bernard B, de Jong M
J Nucl Med
. 2003 Jan;
44(1):98-104.
PMID: 12515882
Unlabelled: Peptide receptor radionuclide therapy (PRRT) using [(111)In-DTPA(0)]octreotide (where DTPA is diethylenetriaminepentaacetic acid) is feasible because, besides gamma-radiation, (111)In emits both therapeutic Auger and internal conversion electrons having a tissue...
15.
de Jong M, Valkema R, Jamar F, Kvols L, Kwekkeboom D, Breeman W, et al.
Semin Nucl Med
. 2002 Apr;
32(2):133-40.
PMID: 11965608
In preclinical studies in rats we evaluated biodistribution and therapeutic effects of different somatostatin analogs, [(111)In-DTPA]octreotide, [(90)Y-DOTA,Tyr(3)]octreotide and [(177)Lu-DOTA,Tyr(3)]octreotate, currently also being applied in clinical radionuclide therapy studies. [Tyr(3)]octreotide and...
16.
Valkema R, de Jong M, Bakker W, Breeman W, Kooij P, Lugtenburg P, et al.
Semin Nucl Med
. 2002 Apr;
32(2):110-22.
PMID: 11965606
Fifty patients with somatostatin receptor-positive tumors were treated with multiple doses of [(111)In-diethylenetriamine pentaacetic acid(0)]octreotide. Forty patients were evaluable after cumulative doses of at least 20 GBq up to 160...